The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules
CMS says the record-keeping will help provide important, real-world information about the benefits and risks of these new drugs.
CMS says the record-keeping will help provide important, real-world information about the benefits and risks of these new drugs.
What's Your Reaction?
